WEC
VNDA icon

Winslow Evans & Crocker’s Vanda Pharmaceuticals VNDA Stock Holding History

Winslow Evans & Crocker’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-366
Closed -$8K – 1341
2019
Q1 		$8K Hold
366
– – ﹤0.01% 892
2018
Q4 		$10K Buy
+366
New +$8.61K ﹤0.01% 785
2017
Q4 		– Sell
-70
Closed -$1.25K – 1159
2017
Q3 		$1.25K Hold
70
– – ﹤0.01% 1051
2017
Q2 		$1.14K Hold
70
– – ﹤0.01% 1207
2017
Q1 		$980 Buy
+70
New +$998 ﹤0.01% 1190

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Winslow Evans & Crocker's VNDA Position: Q2 2019 in Review

Winslow Evans & Crocker sold out of Vanda Pharmaceuticals (VNDA) in Q2 2019, closing a stake of 366 shares — an estimated $8K sold.

Winslow Evans & Crocker first reported a position in VNDA in Q1 2017 and held it in 5 quarters. The position peaked at $10K in Q4 2018. 164 funds tracked by Wall St. Rank hold VNDA as of Q2 2019.

  • Winslow Evans & Crocker reported no remaining Vanda Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Winslow Evans & Crocker sold 366 Vanda Pharmaceuticals shares in Q2 2019, an estimated $8K.
  • Winslow Evans & Crocker first reported a position in Vanda Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Winslow Evans & Crocker's Vanda Pharmaceuticals position peaked at $10K in Q4 2018.
  • 164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2019.

Based on Winslow Evans & Crocker's 13F filing for Q2 2019, filed 19 Jul 2019.